$SYRE Cashflow Statement | Understand Stock

$SYRE

$99.05 +$0.00 (0.0%) After hours

$SYRE Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss
Series B Non-Voting Convertible Preferred Stock
Series A Non-Voting Convertible Preferred Stock
Common Stock
Total net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
Purchase net (premium) discount on marketable securities
Stock-based compensation
Acquired in-process research and development
Change in fair value of derivative liability
Contingent Value Right Liability
Forward Contract Liability
Gain on sale of in-process research and development asset
Lease ROU asset and leasehold improvement impairment loss
Loss on disposal of long-lived assets
Net (accretion of discount) amortization of premium on marketable securities
Interest proceeds from maturities of zero coupon debt securities
Amortization of operating lease assets
Other
Changes in operating assets and liabilities:
Prepaid expenses and other assets
Accounts payable
Deferred revenue
Development receivables
Operating lease liabilities
Accrued and other liabilities
Related party accounts payable

Net cash used in operating activities
CASH FLOWS FROM INVESTING ACTIVITIES
Cash assumed from asset acquisition of Spyre
Proceeds from sale of in-process research & development asset
Purchases of property and equipment
Proceeds from the sale of property plant and equipment
Purchases of marketable securities
Proceeds from maturities and sales of marketable securities
Net cash (used in) provided by investing activities
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of Series A non-voting convertible preferred stock in connection with private placement, net of placement and other offering costs
Proceeds from issuance of private placement, net
Series B Non-Voting Convertible Preferred Stock
Series A Non-Voting Convertible Preferred Stock
Common Stock
Total proceeds from issuance of private placement, net
Proceeds from issuance of common stock in connection with at-the-market offering program, net of issuance costs
Proceeds from issuance of common stock in connection with follow-on offering, net of issuance costs
Payment of deferred offering costs in connection with shelf registration
Proceeds from issuance of common stock and pre-funded warrants in registered direct offering, net of offering costs
Payment of contingent value rights liability
Proceeds from employee stock option exercises and employee stock plan purchases
Principal payments on finance lease obligation
Other financing cash flows
Net cash provided by financing activities
Effect of exchange rate on cash, cash equivalents, and restricted cash
NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH
Beginning of period
End of period
Supplemental Disclosure of Non-Cash Investing and Financing Information:
Unpaid amounts related to purchase of property and equipment
Allocation of deferred offering costs against proceeds of issuance of common stock
Exchange of Series A non-voting convertible preferred stock for common stock
Conversion of non-voting convertible preferred stock into common stock
Series B Non-Voting Convertible Preferred Stock
Series A Non-Voting Convertible Preferred Stock
Total conversion of non-voting convertible preferred stock into common stock
Settlement of forward contract liability and issuance of Series A non-voting convertible preferred stock in connection with the asset acquisition of Spyre
Leased assets obtained in exchange for lease obligations
Reconciliation of Cash, Cash Equivalents, and Restricted Cash Reported in the Statement of Financial Position
Cash and cash equivalents
Restricted cash

Comments